Acarix
- Company typePublic
- Founded2015
- HeadquartersKongens Lyngby, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Acarix firmographics
Firmographics- Name
- Acarix
- Legal name
- Acarix AB (publ)
- Website
- https://acarix.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Acarix industry classification
Industry- Product category
- Cardiac Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
Keywords
Where Acarix is headquartered
LocationHeadquarters
- HQ city
- Kongens Lyngby
- HQ country
- Denmark
- HQ region
- Europe
Offices4 records
Markets served
Acarix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- CADScor System Device Sales: Sale of CADScor medical device systems to healthcare providers, hospitals, and cardiology practices. Q4 2025 saw 23 CADScor Systems delivered, representing 64% growth in device deliveries worldwide.
- CADScor Patch Consumables: Recurring revenue from disposable CADScor patches used during patient assessments. System has been used in over 60,000 patient assessments since 2017 commercial launch.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Enterprise medical device with recurring consumable revenue |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Acarix product offering
Product offeringCore offering
Acarix develops and sells the CADScor System, a point-of-care medical device that uses ultrasensitive acoustic recording (phonocardiography) and an integrated CAD-Score Algorithm to analyze heart sounds and rapidly rule out significant coronary artery disease (CAD) in symptomatic patients. The system is paired with disposable CADScor Patch sensors and produces a patient-specific CAD-score (0-99) in approximately 10 minutes for immediate risk stratification prior to secondary evaluation.
Product overview
Acarix offers the CADScor System as its core medical device product, a point-of-care diagnostic aid for ruling out significant coronary artery disease. The system combines a hardware device with a disposable CADScor Patch sensor and an integrated CAD-Score Algorithm developed with Aalborg University. The product provides rapid (10-minute), non-invasive, radiation-free assessment using acoustic analysis of heart sounds, producing a numerical CAD-score (0-99) for risk stratification. The portfolio is supported by a comprehensive clinical studies program demonstrating the system's performance across over 8,000 patients.
Differentiator
Problem solved
Functional benefit
Products and services
- CADScor System Point-of-care diagnostic aid that uses highly sensitive acoustics (phonocardiography) and advanced computational processing to analyze coronary blood flow and rule out significant coronary artery disease. Calculates a patient-specific CAD-score (0-99) coupled with risk factors for immediate risk stratification prior to secondary evaluation. For cardiology practices, hospitals, and cardiac units evaluating symptomatic patients with suspected CAD.
- CADScor Patch Disposable sensor patch used with the CADScor System for recording heart sounds. Contains a specific chip and code required to calibrate the machine. Each patch can be used up to four times if not removed from the patient's chest. Generates recurring consumable revenue tied to patient assessment volume.
Quantifiable outcome
- 96.2% negative predictive value in United States, 97.2% in European markets
- +4 more outcomes
Companies that use Acarix
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Acarix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Acarix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Saudi Arabia Distribution PartnercoreStrategic distribution partnership for CADScor System in Saudi Arabia targeting regulatory approval and product orders worth approximately SEK 9.8 million within six months after approval. Part of MENA region expansion strategy.
- Aalborg UniversitycoreCollaborative development of the integrated scoring algorithm for CADScor System. University partnership providing academic and research credibility for the acoustic detection technology and algorithm development.
- Saxum (Media Relations)minorMedia relations contact for press inquiries. Contact: Macie May at [email protected], phone +1 405 517 5161.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Acarix competitors and assessment
Company assessmentBroad incumbents
- Philips (Cardiac Care): Philips provides comprehensive cardiac care solutions including imaging, monitoring, and AI-enabled diagnostic tools. As a broad incumbent, it competes for the same cardiology customer relationships and capital purchasing decisions that Acarix targets with its point-of-care CADScor system.
- Boston Scientific: Boston Scientific is a major cardiovascular device company with cardiac diagnostics and monitoring (including its acquisition of Preventice Solutions). It competes in the broader cardiac care space and could be a potential strategic acquirer for Acarix given complementary cardiac monitoring capabilities.
- GE HealthCare: GE HealthCare is a major medical imaging and cardiac diagnostics incumbent offering CT, MRI, and nuclear cardiology solutions. As a broad cardiac diagnostic portfolio player, it competes with Acarix for hospital cardiology budgets and represents the incumbent alternative to novel point-of-care solutions.
Emerging players
- Cardio Diagnostics Holdings: Cardio Diagnostics offers AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment. Both companies are early-stage, AI-powered cardiac diagnostics targeting similar clinical decision points, though Cardio Diagnostics uses blood-based biomarkers while Acarix uses acoustic sensing.
- Viz.ai: Viz.ai applies AI to cardiovascular and neurovascular care coordination and diagnostics. Both companies are AI-focused medical technology players targeting improved clinical decision-making in cardiac care, though Viz.ai focuses on care coordination and stroke while Acarix focuses on CAD rule-out.
- AliveCor: AliveCor provides AI-powered portable ECG devices (KardiaMobile) for cardiac monitoring. Both companies offer non-invasive, AI-enabled cardiac diagnostic tools for point-of-care use, though AliveCor focuses on arrhythmia detection via single-lead ECG rather than CAD detection.
- Elucid Bioimaging: Elucid offers AI-enabled vascular imaging analysis for cardiovascular disease assessment. Both companies apply AI to non-invasive cardiac/vascular diagnostics targeting improved risk stratification, though Elucid focuses on imaging-based plaque analysis.
Direct peers
- Cleerly: Cleerly applies AI to coronary CT angiography for plaque characterization and CAD risk assessment. Both companies offer AI-powered CAD diagnostic aids aimed at improving risk stratification and reducing unnecessary invasive procedures, though Cleerly is imaging-based while CADScor is acoustic-based.
- HeartFlow: HeartFlow provides non-invasive FFR-CT analysis for coronary artery disease assessment. Both companies target rapid CAD rule-out at point of care or in diagnostic workflows, competing for the same cardiology practice customers and hospital budgets, though HeartFlow uses CT imaging while Acarix uses acoustic sensing.
- iRhythm Technologies: iRhythm's Zio patch is a wearable adhesive cardiac monitoring patch. Both companies use patch-based cardiac diagnostic technology sold to cardiology practices, though iRhythm focuses on arrhythmia detection (Holter-style) while Acarix focuses on CAD rule-out.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Acarix social profiles
Digital presenceAcarix compliance and trust
Trust signalCompliance2 records
Acarix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acarix leadership team
Management profileNumber of profiles
Profiles8 records
Acarix subsidiaries and ownership
Company hierarchySubsidiaries3 records
Acarix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acarix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acarix
What does Acarix do?
Acarix develops and sells the CADScor System, a point-of-care medical device that uses ultrasensitive acoustic recording (phonocardiography) and an integrated CAD-Score Algorithm to analyze heart sounds and rapidly rule out significant coronary artery disease (CAD) in symptomatic patients. The system is paired with disposable CADScor Patch sensors and produces a patient-specific CAD-score (0-99) in approximately 10 minutes for immediate risk stratification prior to secondary evaluation.
Is Acarix a public or private company?
Acarix is a public company. It is classified as public and is currently operating.
When was Acarix founded?
Acarix was founded in 2015. It employs 1 to 10 people.
Where is Acarix based?
Acarix is headquartered in Kongens Lyngby, Denmark, in the Europe region.
How does Acarix make money?
Two revenue lines are on record. CADScor System Device Sales are the primary driver. The others are CADScor Patch Consumables.
Who are Acarix's main competitors?
Broad incumbents on record are Philips (Cardiac Care), Boston Scientific and GE HealthCare. Emerging players are Cardio Diagnostics Holdings, Viz.ai, AliveCor and Elucid Bioimaging. Direct peers are Cleerly, HeartFlow and iRhythm Technologies.
Does Acarix have an API?
No public API is recorded for Acarix.
What industry is Acarix in?
Acarix's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.